Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 16/20 | 0.81 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.81 |
| ▸ | CDK4 | P11802 | 11/20 | 0.68 |
| ▸ | CDK1 | P06493 | 4/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.54 |
| ▸ | CCND3 | P30281 | 4/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25695256 | 0.92 | CCND1 (0.80) | CCND1CDK6CDK4CCNA2CCND3 | |
| SCHEMBL29497098 | 0.90 | CCND1 (1.00) | CCND1CDK6CDK4 | |
| SCHEMBL25283091 | 0.90 | CCND1 (1.00) | CCND1CDK6CDK4 | |
| SCHEMBL24322174 | 0.88 | CCND1 (0.72) | CCND1CDK6CDK4CDK1CCNA2 | |
| SCHEMBL24322113 | 0.85 | CCND1 (0.73) | CCND1CDK6CDK4CDK1CCNA2 | |
| SCHEMBL29514983 | 0.85 | CCND1 (0.73) | CCND1CDK6CDK4CDK1CCNA2 | |
| SCHEMBL29515046 | 0.84 | CCND1 (0.80) | CCND1CDK6CDK4 | |
| SCHEMBL24322172 | 0.84 | CCND1 (0.80) | CCND1CDK6CDK4 | |
| SCHEMBL25695292 | 0.83 | CCND1 (0.83) | CCND1CDK6CDK4CCNA2CCND3 | |
| SCHEMBL24322965 | 0.83 | CCND1 (1.00) | CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK6 1/4885CDK4 12/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK6 1/4885CDK4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.